The diagnosis of avoidant restrictive food intake disorder in the presence of gastrointestinal disorders: Opportunities to define shared mechanisms of symptom expression
Abstract:Objective
Individuals with a gastrointestinal (GI) disorder often alter their diet to manage GI symptoms, adding complexity to understanding the diverse motivations contributing to food avoidance/restriction. When a GI disorder is present, the DSM‐5 states that Avoidant/Restrictive Food Intake Disorder (ARFID) can be diagnosed only when eating disturbance exceeds that expected. There is limited guidance to make this determination. This study attempts to address this gap by characterizing the presentation of AR… Show more
“…In addition to these results, one study from 2020 reported that over 60% of children with ARFID admitted to a paediatric hospital had some past history of GI problems (Tsang et al., 2020 ). These estimates, although different from each other, suggest that there might be an overlap between ARFID and GI problems, which could be important for understanding the aetiology of some presentations (Nicholas et al., 2021 ). The presence of GI symptoms together with ARFID should inform case formulation with assessment and intervention for GI symptoms being a clinical priority in this patient group (Boerner et al., 2021 ; Nicholas et al., 2021 ).…”
Background: Avoidant/restrictive food intake disorder (ARFID) was a new diagnosis in DSM-5. This systematic review explores what is known to date about the epidemiology of ARFID in children and adolescents. Method: Embase, Medline and PsycInfo were used to identify studies meeting inclusion criteria. PRISMA guidelines were followed. Results: Thirty studies met inclusion criteria, with most coming from specialised eating disorder services where prevalence rates were 5%-22.5%. Three studies from specialist feeding clinics showed the highest prevalence rates, ranging from 32% to 64%. Studies from non-clinical samples reported ARFID prevalence estimates ranging from 0.3% to 15.5%. One study, using national surveillance methodology, reported the incidence of ARFID in children and adolescents reaching clinical care to be 2.02 per 100,000 patients. Psychiatric comorbidity was common, especially anxiety disorders (9.1%-72%) and autism spectrum disorder (8.2%-54.75%).
Conclusion:The current literature on the epidemiology of ARFID in children and adolescents is limited. Studies are heterogeneous with regard to setting and sample characteristics, with a wide range of prevalence estimates. Further studies, especially using surveillance methodology, will help to better understand the nature of this disorder and estimate clinical service needs.
“…In addition to these results, one study from 2020 reported that over 60% of children with ARFID admitted to a paediatric hospital had some past history of GI problems (Tsang et al., 2020 ). These estimates, although different from each other, suggest that there might be an overlap between ARFID and GI problems, which could be important for understanding the aetiology of some presentations (Nicholas et al., 2021 ). The presence of GI symptoms together with ARFID should inform case formulation with assessment and intervention for GI symptoms being a clinical priority in this patient group (Boerner et al., 2021 ; Nicholas et al., 2021 ).…”
Background: Avoidant/restrictive food intake disorder (ARFID) was a new diagnosis in DSM-5. This systematic review explores what is known to date about the epidemiology of ARFID in children and adolescents. Method: Embase, Medline and PsycInfo were used to identify studies meeting inclusion criteria. PRISMA guidelines were followed. Results: Thirty studies met inclusion criteria, with most coming from specialised eating disorder services where prevalence rates were 5%-22.5%. Three studies from specialist feeding clinics showed the highest prevalence rates, ranging from 32% to 64%. Studies from non-clinical samples reported ARFID prevalence estimates ranging from 0.3% to 15.5%. One study, using national surveillance methodology, reported the incidence of ARFID in children and adolescents reaching clinical care to be 2.02 per 100,000 patients. Psychiatric comorbidity was common, especially anxiety disorders (9.1%-72%) and autism spectrum disorder (8.2%-54.75%).
Conclusion:The current literature on the epidemiology of ARFID in children and adolescents is limited. Studies are heterogeneous with regard to setting and sample characteristics, with a wide range of prevalence estimates. Further studies, especially using surveillance methodology, will help to better understand the nature of this disorder and estimate clinical service needs.
“…Both groups had similar frequencies of physical symptoms, though patients diagnosed with SSRD had more co-occurring medical conditions. The high proportion of patients with ARFID reporting GI symptoms (84%) may be relevant to understanding the underlying etiology of certain presentations of this diagnosis that may overlap with GI disorders, including central sensitization ( Sim et al, 2021 ) and interactions of altered gut physiology with symptom-related distress and fear-learning ( Nicholas et al, 2021 ; Wildes et al, 2021 ). However, it is also possible that some of the reported GI concerns were consequences of malnutrition, such as constipation, rather than an initiating factor for the eating disturbance.…”
Certain presentations of Avoidant/Restrictive Food Intake Disorder (ARFID) and Somatic Symptom and Related Disorders (SSRDs) have conceptual overlap, namely, distress and impairment related to a physical symptom. This study compared characteristics of pediatric patients diagnosed with ARFID to those with gastrointestinal (GI)-related SSRD. A 5-year retrospective chart review at a tertiary care pediatric hospital comparing assessment data of patients with a diagnosis of ARFID ( n = 62; 69% girls, Mage = 14.08 years) or a GI-related SSRD ( n = 37; 68% girls, Mage = 14.25 years). Patients diagnosed with ARFID had a significantly lower percentage of median BMI than those with GI-related SSRD. Patients diagnosed with ARFID were most often assessed in the Eating Disorders Program, whereas patients diagnosed with an SSRD were most often assessed by Consultation-Liaison Psychiatry. Groups did not differ on demographics, psychiatric diagnoses, illness duration, or pre-assessment services/medications. GI symptoms were common across groups. Patients diagnosed with an SSRD had more co-occurring medical diagnoses. A subset (16%) of patients reported symptoms consistent with both diagnoses. Overlap is observed in the clinical presentation of pediatric patients diagnosed with ARFID or GI-related SSRD. Some group differences emerged, including anthropometric measurements and co-occurring medical conditions. Findings may inform diagnostic classification and treatment approach.
“…Among those with DGBI, disordered eating patterns (such as food restriction, binge eating, purging) ranges from 5% to 44% 28 . More recently, the phenomenon of ARFID in DGBI has been recognized with cross-sectional and retrospective studies 4,10,11,29–36 …”
Section: The Relevance Of Arfid In Dgbismentioning
confidence: 99%
“…Differences in self-report frequencies may be due to varying cutoffs applied across studies on one ARFID screening questionnaire [the Nine-Item ARFID Screen (NIAS)], 38,39 as well as characteristics of the clinical populations. Finally, a cross-sectional self-report survey study found that among a community of self-identified “picky eater” adults who self-reported DGBI symptoms, 11% met the diagnostic criteria for ARFID 31 . To our knowledge, no study to date has investigated the frequency of ARFID in DGBI using semistructured or clinician interview (the gold standard for diagnosis of eating disorders), thus current frequency estimates are limited by the use of self-report surveys.…”
Section: The Relevance Of Arfid In Dgbismentioning
High rates of overlap exist between disorders of gut-brain interaction (DGBI) and eating disorders, for which common interventions conceptually conflict. There is particularly increasing recognition of eating disorders not centered on shape/weight concerns, specifically avoidant/restrictive food intake disorder (ARFID) in gastroenterology treatment settings. The significant comorbidity between DGBI and ARFID highlights its importance, with 13% to 40% of DGBI patients meeting full criteria for or having clinically significant symptoms of ARFID. Notably, exclusion diets may put some patients at risk for developing ARFID and continued food avoidance may perpetuate preexisting ARFID symptoms. In this review, we introduce the provider and researcher to ARFID and describe the possible risk and maintenance pathways between ARFID and DGBI. As DGBI treatment recommendations may put some patients at risk for developing ARFID, we offer recommendations for practical treatment management including evidence-based diet treatments, treatment risk counseling, and routine diet monitoring. When implemented thoughtfully, DGBI and ARFID treatments can be complementary rather than conflicting.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.